Tielong Wang

Dr. Tielong Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Liver Transplantation
Verified
Journal Article
Open access
TWTielong Wang
Tielong Wang
ZCZhitao Chen
Zhitao Chen
YLYao Liu
Yao Liu
YJYu Jia
Yu Jia
WJWeiqiang Ju
Weiqiang Ju
XHXiaoshun He
Xiaoshun He
Immune checkpoint inhibitors (ICIs) may lead to rejection and even graft loss of solid organ transplant recipients, making them not widely used in transplant patients. There is insufficient clinical experience in using ICIs as a bridging or downstaging therapy before transplantation. We performed a retrospective review of patients receiving programmed cell death 1 inhibitor (PD1) before liver transplantation for HCC in our center and analyzed the data of these patients with the purpose of investigating the safety and feasibility of preoperative PD1 inhibitor among liver transplant recipients and exploring the preoperative correlation ICIs and the postoperative risk of rejection and immune-related graft loss. A total of 16 patients enrolled in this study. Acute rejection occurred in 9 patients, with an incidence of 56.3%. The median time of rejection was 7 days after surgery. The median FK506 concentration at the time of rejection was 7.1 μg/L. All rejection reactions were reversed after adjusting the immunosuppression regimen. The interval between the last PD1 inhibitor and transplantation in the rejection group was shorter than that in the nonrejection group, and there was a statistical difference [21.0 (15.5–27.5) days vs. 60.0 (34.0–167.0) days, p=0.01]. In conclusion, PD1 inhibitor is a safe and feasible method for bridging or downstaging treatment before liver transplantation. Although preoperative PD1 inhibitor may increase the incidence of postoperative rejection, it is not associated with increased immune-related graft loss and patient death.

9 September 2024 in Annals of Surgery
Verified
Journal Article
Open access
QZQiang Zhao
Qiang Zhao
JLJIahao LI
JIahao LI
ZLZepeng Lin
Zepeng Lin
YTYunhua Tang
Yunhua Tang
DYDaopeng Yang
Daopeng Yang
XHXiaoshun He
Xiaoshun He
Objective: Evaluating the safety and efficacy of implanting a liver with islet grafts into patients with end-stage liver disease and diabetes mellitus (DM). Background: DM and end-stage liver diseases are significant health concerns worldwide, often coexisting and mutually influencing each other. Addressing both diseases simultaneously is paramount. Methods: We utilized the islet transplantation combined ischemia-free liver transplantation technique to treat a patient with hepatocellular carcinoma and type 2 diabetes mellitus. The liver was procured and preserved using the ischemia-free liver transplantation technique, and during normothermic machine perfusion, isolated and purified islet grafts were transplanted into the liver through the portal vein. Finally, the liver, incorporating with the transplant islet grafts, was implanted into the recipient without interruption of blood supply. Results: The patient received both liver and islet grafts from the same donor. The patient achieved insulin-independence by post-transplant day 9, and both liver and islet function remained robust. The patient was discharged on post-transplant day 16 and experienced no surgical or transplantation-related complications during the follow-up period. Furthermore, islet grafts presence was observed in liver biopsies after islet transplantation. Conclusions: This landmark case marks the inaugural application of ischemia-free liver transplantation in humans, signifying its potential as a promising treatment modality for end-stage liver disease with DM.

31 July 2025 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JZJiayi Zhang
Jiayi Zhang
MZMingxi Zhang
Mingxi Zhang
XLXiaorui Liu
Xiaorui Liu
ZJZehua Jia
Zehua Jia
JZJingxing Zhang
Jingxing Zhang
XHXiaoshun He
Xiaoshun He
Liver transplantation (LT) is the main treatment for HCC patients, but postoperative complications such as early allograft dysfunction (EAD), acute rejection (AR), and biliary complications can affect the prognosis of patients. However, whether the occurrence of early complications after transplantation will affect the overall survival and tumor recurrence of patients have not been fully studied. We conducted a retrospective clinical study to evaluate the impact of early complications on overall survival and their relationship with HCC recurrence after liver transplantation. This retrospective study analyzed 378 patients who underwent liver transplantation for HCC between January 2015 and December 2020 at The First Affiliated Hospital, Sun Yat-sen University. The follow-up data of overall survival (OS) and recurrence-free survival (RFS) were collected. Median recurrence-free survival (RFS) was 92.18 months, with RFS rates of 75.9% at 1 year, 60.8% at 3 year, 56.1% at 5 years. 239 (63.2%) patients remained alive following transplantation, and the median overall survival was 100.75 months, with survival rates of 90.5% at 1 year, 71.2% at 3 year, 66.3% at 5years. Multivariate Cox’s regression analysis revealed that postoperative acute rejection (AR) and postoperative early allograft dysfunction (EAD) were independent risk factors for overall survival (OS). AR was the independent risk factors for recurrence-free survival. EAD and AR are independent risk factors for overall survival, and AR is an independent risk factor for recurrence-free survival. Reducing the incidence of EAD, AR and biliary complications after transplantation can effectively improve the overall survival and recurrence-free survival of patients.

14 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
YTYunhua Tang
Yunhua Tang
JLJIahao LI
JIahao LI
TZTao Zhang
Tao Zhang
HCHonghui Chen
Honghui Chen
MQMeiting Qin
Meiting Qin
QZQiang Zhao
Qiang Zhao
The incidence of liver diseases is on the leading rise worldwide, but there is a lack of exact research models mimic liver diseases. Using the normothermic machine perfusion (NMP) platform to study diseased livers recovered from the liver transplantation (LT) recipients seems promising. Therefore, the aim of this study was to establish the first machine perfusion system called Life-XDL to cultivate diseased liver. Four diseased livers recovered from LT recipients within different diagnoses were collected. The diseased livers were connected to the Life-XDL machine perfusion system that circulated Life-XDL perfusate providing oxygen and nutrients. The pressure and flow of the device was recorded and blood gas analysis and laboratory test of perfusate and bile was examined to analyze the function of the diseased livers. Liver tissues after perfusion were collected for histological analysis. Experiments showed that Life-XDL kept the diseased livers at the physiological state with providing stable hemodynamics and suitable partial pressure of oxygen and carbon dioxide. The results of blood gas analysis and laboratory test results demonstrated restoration and maintenance of metabolism and less damage. Moreover, the bile production of case 1, 3 and 4 diseased livers represented its vivid functionality. The pathological characteristics were kept stable before and after NMP. Overall, we successfully establish the Life-XDL machine perfusion system which specially for diseased human whole liver and develop a new diseased human whole organ model in vitro through normothermic machine perfusion that recapitulate the main features of the human liver disease, which showing great promise as disease modeling platforms.

22 January 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JZJiayi Zhang
Jiayi Zhang
WLWei Liu
Wei Liu
XLXiaorui Liu
Xiaorui Liu
XWXu Wang
Xu Wang
KTKai Tang
Kai Tang
XHXiaoshun He
Xiaoshun He
Hepatocellular carcinoma (HCC) originates from hepatocytes and accounts for over 80% of primary liver cancers. Despite numerous studies have explained the role of certain angiogenesis-related and integrated stress response related genes in the development of HCC, few studies have explored the function of all angiogenesis-related and ISR(Integrated stress response)-related genes, as well as their applications in therapeutic prediction models. Here, by integrating bulk and single cell transcriptome data, We first explored the expression patterns of genes at the intersection of angiogenesis and the integrated stress response (ISR). To comprehensively identify angiogenesis-related gene modules, we then performed WGCNA (weighted gene co-expression network analysis) using a broader angiogenesis gene set, revealing modules strongly correlated with angiogenic activity.Based on these core genes, we constructed a prognostic model to evaluate patient outcomes and responses to immunotherapy, which is valuable for informing treatment options. Furthermore, through drug response modeling, we identified several drugs targeting angiogenesis genes that could serve as potential therapeutic options. Single-cell transcriptome analysis also revealed that DAB2, which is highly expressed in APOA2+ macrophages, may be involved in the cellular response to signals from fibroblast cells via the THY1 pathway. Finally, molecular docking studies indicated that dihydroergotamine might be a promising candidate drug for targeting DAB2. This study systematically investigated the expression changes of angiogenesis genes in HCC, constructed a tumor prognosis prediction model, and explored potential therapeutic targets and drugs. These findings are of significance for guiding the selection of treatment options and identifying therapeutic targets for HCC.

11 September 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
YTYunhua Tang
Yunhua Tang
JLJIahao LI
JIahao LI
MQMeiting Qin
Meiting Qin
ZLZhiying Liu
Zhiying Liu
JKJun Kang
Jun Kang
QZQiang Zhao
Qiang Zhao
Acute-on-chronic liver failure (ACLF) is a life-threatening condition with high mortality. Ischemia-free liver transplantation (IFLT), a novel clinical approach avoiding ischemia-reperfusion injury, may offer significant benefits for ACLF patients. This study included 30 ACLF patients undergoing IFLT and 97 ACLF patients undergoing conventional liver transplantation (CLT). After propensity score matching (PSM), the IFLT group comprised 28 patients, while the CLT group had 51 patients. In the PSM cohort, Kaplan-Meier analysis confirmed IFLT improved patient and graft survival for ACLF patients (log rank P=0.018 and 0.018, respectively). The IFLT group demonstrated better six-month patient survival rates (100% vs 74.5%, P=0.009) and lower post-reperfusion syndrome, shorter operative time, reduced intraoperative blood loss, less blood products use. Furthermore, ACLF patients receiving IFLT experienced fewer early allograft dysfunction, reduced intensive care unit stays, earlier extubation, faster consciousness recovery, shorter time to first flatus. Accelerated recovery of liver, circulatory, respiratory, coagulation functions were observed in the IFLT group, along with fewer acute kidney injury. Notably, ACLF patients receiving ECD livers in the IFLT group achieved better survival and clinical outcomes. Consequently, IFLT enhanced the survival rates and promoted the recovery of remote organs in ACLF patients, and improved clinical prognoses for those receiving ECD livers.